EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 390 filers reported holding EXELIXIS INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,759,865 | +14.5% | 309,376 | +0.2% | 0.02% | +23.1% |
| Q2 2023 | $5,903,003 | -4.9% | 308,896 | -3.4% | 0.01% | -7.1% |
| Q1 2023 | $6,207,202 | +21.2% | 319,794 | +0.1% | 0.01% | +7.7% |
| Q4 2022 | $5,123,432 | -3.0% | 319,416 | -5.2% | 0.01% | -7.1% |
| Q3 2022 | $5,284,000 | -24.7% | 336,976 | 0.0% | 0.01% | -17.6% |
| Q2 2022 | $7,016,000 | -10.3% | 336,976 | -2.4% | 0.02% | +13.3% |
| Q1 2022 | $7,825,000 | -9.5% | 345,181 | -27.0% | 0.02% | -6.2% |
| Q4 2021 | $8,643,000 | +16.8% | 472,806 | +35.1% | 0.02% | +14.3% |
| Q3 2021 | $7,397,000 | +14.6% | 349,883 | -1.2% | 0.01% | +16.7% |
| Q2 2021 | $6,452,000 | -19.4% | 354,123 | 0.0% | 0.01% | -25.0% |
| Q1 2021 | $8,000,000 | -2.7% | 354,123 | -13.6% | 0.02% | -5.9% |
| Q4 2020 | $8,224,000 | -13.0% | 409,780 | +6.0% | 0.02% | -22.7% |
| Q3 2020 | $9,452,000 | -9.8% | 386,603 | -12.5% | 0.02% | -15.4% |
| Q2 2020 | $10,484,000 | +30.5% | 441,606 | -5.4% | 0.03% | +8.3% |
| Q1 2020 | $8,034,000 | -4.4% | 466,577 | -2.2% | 0.02% | +14.3% |
| Q4 2019 | $8,406,000 | +4.2% | 477,099 | +4.6% | 0.02% | 0.0% |
| Q3 2019 | $8,064,000 | -17.7% | 455,972 | -0.5% | 0.02% | -16.0% |
| Q2 2019 | $9,793,000 | -10.1% | 458,250 | +0.2% | 0.02% | -13.8% |
| Q1 2019 | $10,888,000 | +18.8% | 457,491 | -1.8% | 0.03% | +7.4% |
| Q4 2018 | $9,164,000 | +31.8% | 465,876 | +18.7% | 0.03% | +50.0% |
| Q3 2018 | $6,954,000 | -17.7% | 392,434 | 0.0% | 0.02% | -21.7% |
| Q2 2018 | $8,445,000 | -1.5% | 392,434 | +1.4% | 0.02% | -4.2% |
| Q1 2018 | $8,575,000 | -27.5% | 387,114 | -0.4% | 0.02% | -22.6% |
| Q4 2017 | $11,820,000 | +26.9% | 388,814 | +1.1% | 0.03% | +24.0% |
| Q3 2017 | $9,318,000 | -0.3% | 384,547 | +1.3% | 0.02% | -3.8% |
| Q2 2017 | $9,350,000 | +188.6% | 379,607 | +153.9% | 0.03% | +188.9% |
| Q1 2017 | $3,240,000 | +45.4% | 149,498 | 0.0% | 0.01% | +28.6% |
| Q4 2016 | $2,229,000 | +13.8% | 149,498 | -2.4% | 0.01% | +16.7% |
| Q3 2016 | $1,959,000 | +62.6% | 153,178 | -0.7% | 0.01% | +50.0% |
| Q2 2016 | $1,205,000 | +95.3% | 154,318 | 0.0% | 0.00% | +100.0% |
| Q1 2016 | $617,000 | -29.1% | 154,318 | 0.0% | 0.00% | -33.3% |
| Q4 2015 | $870,000 | +0.5% | 154,318 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $866,000 | +49.3% | 154,318 | 0.0% | 0.00% | +50.0% |
| Q2 2015 | $580,000 | +46.1% | 154,318 | 0.0% | 0.00% | +100.0% |
| Q1 2015 | $397,000 | +78.8% | 154,318 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $222,000 | -5.9% | 154,318 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $236,000 | -54.9% | 154,318 | 0.0% | 0.00% | -50.0% |
| Q2 2014 | $523,000 | -4.2% | 154,318 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $546,000 | -42.3% | 154,318 | 0.0% | 0.00% | -33.3% |
| Q4 2013 | $946,000 | +5.3% | 154,318 | 0.0% | 0.00% | 0.0% |
| Q3 2013 | $898,000 | +28.1% | 154,318 | 0.0% | 0.00% | +50.0% |
| Q2 2013 | $701,000 | – | 154,318 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |